Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 818672, 8 pages
http://dx.doi.org/10.4061/2011/818672
Review Article

The Molecular Pathogenesis and Clinical Implications of Hepatocellular Carcinoma

Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-Ku, Sapporo, Hokkaido 060-8543, Japan

Received 1 April 2011; Accepted 5 October 2011

Academic Editor: Daisuke Morioka

Copyright © 2011 Makoto Meguro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. F. Kanwal, T. Hoang, J. R. Kramer et al., “Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection,” Gastroenterology, vol. 140, no. 4, pp. 1182–1188, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. Y. F. Xu, Y. Yi, S. J. Qiu et al., “PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection,” Journal of Hepatology, vol. 53, no. 5, pp. 872–879, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Petta and A. Craxì, “Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association,” Current Pharmaceutical Design, vol. 16, no. 6, pp. 741–752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Page and S. A. Harrison, “NASH and HCC,” Clinics in Liver Disease, vol. 13, no. 4, pp. 631–647, 2009. View at Google Scholar
  6. Y. Qian and J. G. Fan, “Obesity, fatty liver and liver cancer,” Hepatobiliary and Pancreatic Diseases International, vol. 4, no. 2, pp. 173–177, 2005. View at Google Scholar · View at Scopus
  7. H. B. El-Serag, T. Tran, and J. E. Everhart, “Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma,” Gastroenterology, vol. 126, no. 2, pp. 460–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. N. Amarapurkar, N. D. Patel, and P. M. Kamani, “Impact of diabetes mellitus on outcome of HCC,” Annals of Hepatology, vol. 7, no. 2, pp. 148–151, 2008. View at Google Scholar · View at Scopus
  9. K. Morita, A. Taketomi, Y. Soejima et al., “De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation,” Liver Transplantation, vol. 15, no. 11, pp. 1412–1416, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Y. Koike, K. Nakagawa, Y. Shiratori et al., “Factors affecting the prognosis of patients with hepatocellular carcinoma invading the portal vein—a retrospective analysis using 952 consecutive HCC patients,” Hepato-Gastroenterology, vol. 50, no. 54, pp. 2035–2039, 2003. View at Google Scholar · View at Scopus
  11. H. C. Hsu, J. C. Sheu, and Y. H. Lin, “Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan: a comparison with resected large HCC,” Cancer, vol. 56, no. 3, pp. 672–680, 1985. View at Google Scholar · View at Scopus
  12. S. Eguchi, T. Kanematsu, S. Arii et al., “Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey,” Surgery, vol. 143, no. 4, pp. 469–475, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. Hwang, S. G. Lee, and J. Belghiti, “Liver transplantation for HCC: its role—eastern and western perspectives,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 17, no. 4, pp. 443–448, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Bojanović, P. Bosnjaković, M. Stojanović et al., “Precision TACE in therapy of primary malignant tumors of liver/hepatocellular carcinoma (HCC),” Acta Chirurgica Lugoslavica, vol. 56, no. 4, pp. 143–148, 2009. View at Publisher · View at Google Scholar
  15. P. R. Mueller, “Percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC),” Japanese Journal of Cancer Research, vol. 86, no. 11, pp. 1244–1245, 1995. View at Google Scholar
  16. K. Witczak-Malinowska, D. Zadrozny, M. Studniarek et al., “Preliminary assessment of utility of radiofrequency ablation technique in treatment of primary hepatocellular carcinoma (HCC) in patients with hepatic cirrhosis,” Medical Science Monitor, vol. 9, supplement 3, pp. 68–72, 2003. View at Google Scholar · View at Scopus
  17. Y. C. Shen, C. Hsu, and A. L. Cheng, “Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives,” Journal of Gastroenterology, vol. 45, no. 8, pp. 794–807, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. M. Chun, H. J. Kwon, J. Sohn et al., “Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma,” Journal of Surgical Oncology, vol. 103, no. 2, pp. 148–151, 2011. View at Publisher · View at Google Scholar
  19. Q. Li, B. Xu, L. Fu, and X. S. Hao, “Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 3, pp. 403–409, 2006. View at Google Scholar · View at Scopus
  20. P. Stock, D. Monga, X. Tan, A. Micsenyi, N. Loizos, and S. P. S. Monga, “Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer,” Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 1932–1941, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. E. Schiffer, C. Housset, W. Cacheux et al., “Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis,” Hepatology, vol. 41, no. 2, pp. 307–314, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. O. N. El-Assal, A. Yamanoi, T. Ono, H. Kohno, and N. Nagasue, “The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma,” Clinical Cancer Research, vol. 7, no. 5, pp. 1299–1305, 2001. View at Google Scholar · View at Scopus
  23. M. A. Feitelson, J. Pan, and Z. Lian, “Early molecular and genetic determinants of primary liver malignancy,” Surgical Clinics of North America, vol. 84, no. 2, pp. 339–354, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. Sǎftoiu, T. Ciurea, M. Baniţǎ et al., “Immunohistochemical assessment of angiogenesis in primary hepatocellular carcinoma,” Romanian Journal of Gastroenterology, vol. 13, no. 1, pp. 3–8, 2004. View at Google Scholar
  25. H. Huynh, T. T. Nguyen, K. H. Chow, P. H. Tan, K. C. Soo, and E. Tran, “Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis,” BMC Gastroenterology, vol. 3, article 19, 2003. View at Publisher · View at Google Scholar · View at PubMed
  26. Y. L. Chen, P. Y. Law, and H. H. Loh, “Inhibition of P13K/Akt signaling: an emerging paradigm for targeted cancer therapy,” Current Medicinal Chemistry—Anti-Cancer Agents, vol. 5, no. 6, pp. 575–589, 2005. View at Google Scholar · View at Scopus
  27. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Printz, “Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM),” Cancer, vol. 115, no. 20, p. 4646, 2009. View at Google Scholar
  30. C. T. Jordan, M. L. Guzman, and M. Noble, “Cancer stem cells,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1253–1261, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. T. Chiba, Y. W. Zheng, K. Kita et al., “Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation,” Gastroenterology, vol. 133, no. 3, pp. 937–950, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. B. E. Petersen, W. C. Bowen, K. D. Patrene et al., “Bone marrow as a potential source of hepatic oval cells,” Science, vol. 284, no. 5417, pp. 1168–1170, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. D. H. Best and W. B. Coleman, “Liver regeneration by small hepatocyte-like progenitor cells after necrotic injury by carbon tetrachloride in retrorsine-exposed rats,” Experimental and Molecular Pathology, vol. 89, no. 2, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. B. Cogliati, T. P. A. Aloia, R. V. Bosch, V. A. F. Alves, F. J. Hernandez-Blazquez, and M. L. Z. Dagli, “Identification of hepatic stem/progenitor cells in canine hepatocellular and cholangiocellular carcinoma,” Veterinary and Comparative Oncology, vol. 8, no. 2, pp. 112–121, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. B. Ma, J. Ren, H. F. Jiang, and J. Jia, “Antitumor activities against hepatocellular carcinoma induced by bone marrow mesenchymal stem cells pulsed with tumor-derived exosomes,” Beijing Da Xue Xue Bao, vol. 40, no. 5, pp. 494–499, 2008. View at Google Scholar · View at Scopus
  36. T. Klonisch, E. Wiechec, S. Hombach-Klonisch et al., “Cancer stem cell markers in common cancers—therapeutic implications,” Trends in Molecular Medicine, vol. 14, no. 10, pp. 450–460, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. D. K. Dhar, T. Ono, A. Yamanoi et al., “Serum endostatin predicts tumor vascularity in hepatocellular carcinoma,” Cancer, vol. 95, no. 10, pp. 2188–2195, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. B. W. Ozanne, H. J. Spence, L. C. McGarry, and R. F. Hennigan, “Transcription factors control invasion: AP-1 the first among equals,” Oncogene, vol. 26, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. L. Chen, Y. Shi, C.-Y. Jiang, L.-X. Wei, Y.-L. Wang, and G.-H. Dai, “Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 37, no. 6, pp. 513–520, 2011. View at Google Scholar
  40. J. Chen and A. Siddiqui, “Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress,” Journal of Virology, vol. 81, no. 12, pp. 6757–6760, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. K. Shimotohno, K. Watashi, K. Tsuchihara, K. Fukuda, H. Marusawa, and M. Hijikata, “Hepatitis C virus and its roles in cell proliferation,” Journal of Gastroenterology, vol. 37, supplement 13, pp. 50–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Avila, C. Berasain, B. Sangro, and J. Prieto, “New therapies for hepatocellular carcinoma,” Oncogene, vol. 25, no. 27, pp. 3866–3884, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. L. R. Roberts and G. J. Gores, “Hepatocellular carcinoma: molecular pathways and new therapeutic targets,” Seminars in Liver Disease, vol. 25, no. 2, pp. 212–225, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. F. Sananbenesi, A. Fischer, C. Schrick, J. Spiess, and J. Radulovic, “Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1,” Molecular and Cellular Neuroscience, vol. 21, no. 3, pp. 463–476, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Halaschek-Wiener, V. Wacheck, Y. Kloog, and B. Jansen, “Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells,” Cellular Signalling, vol. 16, no. 11, pp. 1319–1327, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. K. J. Schmitz, J. Wohlschlaeger, H. Lang et al., “Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection,” Journal of Hepatology, vol. 48, no. 1, pp. 83–90, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. L. R. Roberts and G. J. Gores, “Emerging drugs for hepatocellular carcinoma,” Expert Opinion on Emerging Drugs, vol. 11, no. 3, pp. 469–487, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. K.-F. Chen, H.-L. Chen, W.-T. Tai et al., “Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 155–161, 2011. View at Publisher · View at Google Scholar · View at PubMed
  49. T. H. Hu, C. C. Huang, P. R. Lin et al., “Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma,” Cancer, vol. 97, no. 8, pp. 1929–1940, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. K. Takezawa, I. Okamoto, K. Yonesaka et al., “Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells,” Cancer Research, vol. 69, no. 16, pp. 6515–6521, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. A. X. Zhu, “Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma,” Cancer, vol. 112, no. 2, pp. 250–259, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. M. Höpfner, D. Schuppan, and H. Scherübl, “Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer,” World Journal of Gastroenterology, vol. 14, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar
  53. S. Faivre, E. Raymond, E. Boucher et al., “Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study,” The Lancet Oncology, vol. 10, no. 8, pp. 794–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. X. Zhu, D. V. Sahani, D. G. Duda et al., “Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 3027–3035, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. L. Raoul, R. S. Finn, Y. K. Kang et al., “An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC),” Journal of Clinical Oncology, vol. 27, supplement 1, p. 15S, 2009. View at Google Scholar
  56. P. A. Philip, M. R. Mahoney, C. Allmer et al., “Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6657–6663, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. F. Kanai, H. Yoshida, R. Tateishi et al., “A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 2, pp. 315–324, 2011. View at Publisher · View at Google Scholar · View at PubMed
  58. A. B. Siegel, E. I. Cohen, A. Ocean et al., “Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 2992–2998, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. X. Zhu, K. Stuart, L. S. Blaszkowsky et al., “Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma,” Cancer, vol. 110, no. 3, pp. 581–589, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. B. Thomas, J. S. Morris, R. Chadha et al., “Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 843–850, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. S. Ma, K. W. Chan, L. Hu et al., “Identification and characterization of tumorigenic liver cancer stem/progenitor cells,” Gastroenterology, vol. 132, no. 7, pp. 2542–2556, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. Z. F. Yang, P. Ngai, D. W. Ho et al., “Identification of local and circulating cancer stem cells in human liver cancer,” Hepatology, vol. 47, no. 3, pp. 919–928, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. T. Yamashita, A. Budhu, M. Forgues, and W. W. Xin, “Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma,” Cancer Research, vol. 67, no. 22, pp. 10831–10839, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. S. Inagawa, M. Itabashi, S. Adachi et al., “Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival,” Clinical Cancer Research, vol. 8, no. 2, pp. 450–456, 2002. View at Google Scholar · View at Scopus
  65. W. Song, H. Li, K. Tao et al., “Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma,” International Journal of Clinical Practice, vol. 62, no. 8, pp. 1212–1218, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. L. M. Smith, A. Nesterova, M. C. Ryan et al., “CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers,” British Journal of Cancer, vol. 99, no. 1, pp. 100–109, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. L. Lin, R. Amin, G. I. Gallicano et al., “The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling,” Oncogene, vol. 28, no. 7, pp. 961–972, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. C. B. Rountree, W. Ding, L. He, and B. Stiles, “Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensle homolog deleted on chromosome 10-deleted mice,” Stem Cells, vol. 27, no. 2, pp. 290–299, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. T. Wakamatsu, Y. Nakahashi, D. Hachimine, T. Seki, and K. Okazaki, “The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins,” International Journal of Oncology, vol. 31, no. 6, pp. 1465–1472, 2007. View at Google Scholar · View at Scopus
  70. C. Hu, H. Li, J. Li et al., “Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling,” Carcinogenesis, vol. 29, no. 12, pp. 2289–2297, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. K. Kitisin, N. Ganesan, Y. Tang et al., “Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation,” Oncogene, vol. 26, no. 50, pp. 7103–7110, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. Z. F. Yang, D. W. Ho, M. N. Ng et al., “Significance of CD90+ cancer stem cells in human liver cancer,” Cancer Cell, vol. 13, no. 2, pp. 153–166, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. M. B. Herrera, S. Bruno, S. Buttiglieri et al., “Isolation and characterization of a stem cell population from adult human liver,” Stem Cells, vol. 24, no. 12, pp. 2840–2850, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. K. Endo and T. Terada, “Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival,” Journal of Hepatology, vol. 32, no. 1, pp. 78–84, 2000. View at Google Scholar · View at Scopus
  76. G. H. Yang, J. Fan, Y. Xu et al., “Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection,” Oncologist, vol. 13, no. 11, pp. 1155–1165, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. T. Yamashita, M. Forgues, W. Wang et al., “EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma,” Cancer Research, vol. 68, no. 5, pp. 1451–1461, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. G. Zeng, U. Apte, B. Cieply, S. Singh, and S. P. S. Monga, “siRNA-mediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival,” Neoplasia, vol. 9, no. 11, pp. 951–959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Haraguchi, H. Ishii, K. Mimori et al., “CD13 is a therapeutic target in human liver cancer stem cells,” Journal of Clinical Investigation, vol. 120, no. 9, pp. 3326–3339, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. Y. Inagaki, W. Tang, L. Zhang, G. Du, W. Xu, and N. Kokudo, “Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis,” Bioscience Trends, vol. 4, no. 2, pp. 56–60, 2010. View at Google Scholar · View at Scopus